880
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL INVESTIGATION

Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder

, , , &
Pages 619-624 | Received 19 Nov 2014, Accepted 07 May 2015, Published online: 30 Jul 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ann Childress, Asmara Hoo-Cardiel & Peter Lang. (2020) Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents. Expert Opinion on Pharmacotherapy 21:4, pages 417-426.
Read now

Articles from other publishers (5)

Cian-Cian Lin, Chi-Hsiang ChungWu-Chien ChienNian-Sheng Tzeng. (2023) Pharmacotherapy May Attenuate the Risk of Child Abuse in Attention-Deficit/Hyperactivity Disorder from the Real-World Evidence. Journal of Child and Adolescent Psychopharmacology 33:2, pages 59-68.
Crossref
Wendy Verónica Herrera-Morales, Leticia Ramírez-Lugo, Roger Cauich-Kumul, Eric Murillo-Rodríguez & Luis Núñez-Jaramillo. (2022) Personalization of Pharmacological Treatments for ADHD: Why it is Advisable and Possible Options to Achieve it. Current Topics in Medicinal Chemistry 22:15, pages 1236-1249.
Crossref
Geon Ho Bahn & Kyunghoon Seo. (2021) Combined Medication with Stimulants and Non-stimulants for Attention-deficit/hyperactivity Disorder. Clinical Psychopharmacology and Neuroscience 19:4, pages 705-711.
Crossref
Donghyun Park, Darine Froy N. Mabunga, Keremkleroo Jym Adil, Onjeon Ryu, Schley Valencia, Ryeongeun Kim, Hee Jin Kim, Jae Hoon Cheong, Kyung Ja Kwon, Hahn Young Kim, Seol-Heui Han, Se Jin Jeon & Chan Young Shin. (2021) Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications. Neuropharmacology 187, pages 108494.
Crossref
Haitham Salem, David Vivas, Fei Cao, Iram F. Kazimi, Antonio L. Teixeira & Cristian P. Zeni. (2017) ADHD is associated with migraine: a systematic review and meta-analysis. European Child & Adolescent Psychiatry 27:3, pages 267-277.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.